13 results about "Oxymatrine" patented technology

The invention provides a monascus strain ZX-99 capable of expressing multiple beneficial active substances and application of the monascus strain ZX-99, and belongs to the technical field of microorganisms. The preservation number of the monascus strain ZX-99 provided by the invention is CGMCC No.40962, the strain does not produce citrinin (the detection limit is 25 mg / kg), and compared with other monascus cheese and commercially available mould cheese, the prepared cheese sample has the advantages that the content of citrinin in the cheese sample is greatly reduced, and the content of citrinin in the cheese sample is greatly reduced. Substances such as oxymatrine, bufalin, azadirachtin, gamma-aminobutyric acid, hydroxybenzylamine, maleic acid, maltotriose, maltotetraose and diacetyl are enriched in the monascus cheese ZX-99, and the monascus cheese ZX-99 is expected to be used for developing biological functional dairy products or compounding flavor strains.

The invention relates to a double-drug liposome co-carrying oxymatrine and an STING agonist prodrug as well as a preparation method and application of the double-drug liposome. The double-drug liposome comprises a drug carrier and oxymatrine, wherein the drug carrier consists of a membrane material; the oxymatrine is loaded in a hydrophilic inner cavity of the carrier; the membrane material is prepared from distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine-polyethylene glycol and a cholesterol-STING agonist prodrug conjugate; the cholesterol-STING agonist prodrug conjugate is a conjugate formed by coupling an STING agonist prodrug with cholesterol through a chemical bond. According to the invention, the traditional Chinese medicine active component oxymatrine and the STING agonist prodrug are creatively integrated into the same liposome, so that synergistic controlled release and mechanism complementation can be realized; wherein the STING prodrug is embedded into the carrier in a chemical bond coupling manner, so that drug leakage caused by physical entrapment is avoided, the acute toxicity of the free STING agonist is remarkably reduced, and meanwhile, the innate immune activation capability of the free STING agonist is enhanced.

The application provides mefenamic acid-oxymatrine co-amorphous substance and a preparation method and application thereof, and belongs to the technical field of medicines. The mefenamic acid-oxymatrine co-amorphous substance is composed of mefenamic acid and oxymatrine with a molar ratio of 1:(0.5-3), and the co-amorphous substance is prepared by a grinding method or a solution crystallization method. The mefenamic acid-oxymatrine co-amorphous substance provided by the application has good stability, can significantly improve the solubility of mefenamic acid in water, thereby improving the bioavailability of mefenamic acid, and can also have synergistic effect.

The application belongs to the technical field of biological medicine, and specifically discloses application of seco-oxymatrine in preparation of an antidepressant, wherein the antidepressant further contains a pharmaceutically acceptable carrier; the antidepressant is one of an oral preparation, an inhalant and an injection; the oral preparation is one of a suspension, an emulsion, a solution, a powder, a tablet, a granule and a capsule. When seco-oxymatrine is used as an effective component of the antidepressant, the depressive behavior of a LPS-induced depressive model mouse can be effectively improved.

The invention discloses a method for detecting effective components of a cervicitis treatment composition, which adopts high performance liquid chromatography for detection, and the chromatographic conditions are as follows: a chromatographic column is a C18 chromatographic column; the detection wavelength is 207 nm; a mobile phase A is a 0.2% phosphoric acid aqueous solution, a mobile phase B is acetonitrile, gradient elution is adopted, the mobile phase proportion is volume percent, and the elution procedure is as follows: 0-5 min, the mobile phase A is 100%, and the mobile phase B is 0%; the mobile phase A accounts for 100%-96% and the mobile phase B accounts for 0%-4% in 5-40 min; 40-60 min, the mobile phase A is 88%-58%, and the mobile phase B is 12%-42%; the mobile phase A accounts for 92% and the mobile phase B accounts for 8% in 60-80 min. The method disclosed by the invention can be used for simultaneously determining the components such as sophocarpidine, sophoridine, oxymatrine and amygdalin in the cervicitis composition, is convenient to operate, accurate in detection result and good in stability, and has very high practicability.

The invention discloses application of oroxin B in preparation of a medicine for promoting osteogenic differentiation of bone marrow mesenchymal stem cells, hydrogel of the oroxin B and a preparation method of the hydrogel, and belongs to the technical field of biomedical materials. The invention firstly provides application of oroxin B in preparation of a medicine for promoting osteogenic differentiation of bone marrow mesenchymal stem cells. The invention also provides a self-assembled polypeptide hydrogel loaded with the oroxin B. The hydrogel is obtained by combining the oroxin B with the self-assembled polypeptide with a specific sequence (SEQ ID No.1) and carrying out mild physical blending and incubation. The hydrogel forms a three-dimensional nanofiber network, can entrap and continuously release oroxin B in situ, not only can effectively collect bone marrow mesenchymal stem cells, but also can provide an ideal microenvironment for proliferation and osteogenic differentiation of the bone marrow mesenchymal stem cells, and remarkably up-regulate osteogenic related gene expression, so that bone defect repair is expected to be accelerated.

The application provides a flufenamic acid-oxymatrine co-amorphous substance and a preparation method and application thereof, and belongs to the technical field of medicines.The flufenamic acid-oxymatrine co-amorphous substance is composed of flufenamic acid and oxymatrine in a molar ratio of 3:1-1:3, and the co-amorphous substance is prepared by a grinding method or a solution crystallization method.The flufenamic acid-oxymatrine co-amorphous substance has good stability, can significantly improve the solubility of flufenamic acid in water, thereby improving the bioavailability of flufenamic acid, and can also have synergistic effects.

The invention belongs to the technical field of biomedical materials. The invention provides a preparation method of an ultrasonic piezoelectric composite scaffold for promoting bone repair, which comprises the following steps: mixing oxymatrine and saikoside C as a mixed medicine; the mixed medicine and a stent obtained by sintering hollow barium titanate nanoparticles and hydroxyapatite powder and performing high-pressure polarization treatment are jointly placed in water, after adsorption equilibrium is achieved through stirring, the free mixed medicine is removed, and the ultrasonic piezoelectric composite stent for promoting bone repair is obtained. Wherein the weight ratio of the oxymatrine to the saikoside C is (3-5): 1, and the weight ratio of the hollow barium titanate nanoparticles to the hydroxyapatite powder is 1: 1. According to the invention, the effect of the stent material and the carried medicine on promoting bone repair is fully exerted, the synergistic effect of the material and the carried medicine on promoting osteogenic differentiation is realized, and the stent has a good application prospect.

The application discloses a quality control method of radix stephaniae tetrandrae decoction pieces, adopts liquid chromatography-mass spectrometry to detect the efficacy components in the radix stephaniae tetrandrae decoction pieces, and the efficacy components include any one or several of tetrandrine, fangchinoline, cycilanol, stepholidine, oxystepholidine, stephaoxime, corynoxeine, miliradin and oxymatrine. The specific detection condition can detect multiple efficacy components in the radix stephaniae tetrandrae decoction pieces, which is helpful for comprehensively controlling the quality of the radix stephaniae tetrandrae decoction pieces, and finding the possibility of replacing wild radix stephaniae tetrandrae through efficacy evaluation. In addition, the thin layer chromatography is used to identify the radix stephaniae tetrandrae decoction pieces before detection, and the identification sensitivity can be improved by adjusting the thin layer chromatography condition.

The invention discloses a fingerprint spectrum detection method for yin-nourishing and stomach-clearing granules based on multi-component substances, and belongs to the technical field of quality control of traditional Chinese medicine preparations. According to the method, a high performance liquid chromatography-mass spectrometry technology is adopted, 5-hydroxymethylfurfural, oxymatrine, neomangiferin, mangiferin, forsythiaside A, rutin, tectoridin, naringin, iridoside, naringenin and irisflorentin are taken as reference substances, different batches of test products are detected by optimizing extraction conditions and chromatographic parameters, and the fingerprint spectrum is successfully constructed. The method is simple and easy to implement, high in precision and good in reproducibility, multi-component synchronous identification can be achieved at a time, the detection efficiency is greatly improved, and time and cost are saved; quality monitoring can be accurately, rapidly and simultaneously carried out on a plurality of characteristic components of the Yin-nourishing and stomach-clearing granules, and a powerful guarantee is provided for controlling the quality and ensuring the clinical curative effect of the Yin-nourishing and stomach-clearing granules.

The present application relates to biomedical functional materials and nano drug delivery technology, and particularly relates to a double-response nano hydrogel for promoting chronic wound healing of diabetes, a preparation method and application. The hydrogel is stable in delivery of miR-144-5p by constructing chitosan / sodium tripolyphosphate / hyaluronic acid nanoparticles, and is synergistically loaded with oxymatrine in a gelatin-TG enzyme crosslinking hydrogel matrix, so that in-situ gelation and sequential release of double functional drugs are realized under body temperature. Animal experiments prove that the composition can significantly accelerate wound closure, improve VEGF and CD31 expression and reconstruct dermal vascular network, and has good biocompatibility and controlled release performance, and has a wide clinical application prospect.

This invention provides a high-yield cultivation method for rice-Houttuynia cordata rotation, belonging to the field of crop rotation technology. The method provided by this invention can significantly improve the yield and commercial quality of both rice and Houttuynia cordata, reduce the input of chemical fertilizers, pesticides, and irrigation water, and lower the intensity of farming labor and production costs. Simultaneously, it effectively improves soil physical and chemical properties, increases soil organic matter content and fertilizer retention capacity, reduces agricultural non-point source pollution, and realizes the circular utilization of agricultural resources. It has broad application prospects and good ecological and economic benefits in rice-herbicide rotation areas.

The present application relates to a polysaccharide modified drug phospholipid complex, wherein the drug phospholipid complex is prepared from a drug and a phospholipid, the drug includes oxymatrine and glycyrrhizin, and the polysaccharide modification is that the drug phospholipid complex is first modified by chitosan, and then the drug phospholipid complex coated with chitosan is modified by hyaluronic acid. The polysaccharide modified drug phospholipid complex of the present application can enhance the drug accumulation in tumor cells through synergistic effect and active targeting, and significantly improve the anti-tumor effect of the drug.